News

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for class

Phil Taylor AstraZeneca, breast cancer, camizestrant, Oncology, SABCS, serd 0 Comment

The results of the SERENA-2 trial of AstraZeneca’s oral selective estrogen receptor degrader (SERD) camizestrant, reported at the

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for class

https://pharmaphorum.com/news/sabcs-azs-oral-serd-data-may-relaunch-enthusiasm-for-class/

Radiology technician examens mammography test

News/ News/ News/ Oncology/ R&D

SABCS: New ADC from AZ and Daiichi shows promise in breast cancer

Phil Taylor antibody-drug conjugate, AstraZeneca, breast cancer, Daiichi Sankyo, datopotamab deruxtecan, Enhertu, Oncology, SABCS 0 Comment

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results

SABCS: New ADC from AZ and Daiichi shows promise in breast cancer

https://pharmaphorum.com/news/sabcs-new-adc-from-az-and-daiichi-shows-promise-in-breast-cancer/

Cancer/ News/ News/ News/ Oncology/ R&D

Autolus announces primary endpoint met in FELIX trial, prices public offering

Nicole Raleigh acute lymphoblastic leukaemia, Autolus, CAR T Cell Therapy, obe-cel, share pricing, Syncona 0 Comment

Autolus Therapeutic Plc. (Nasdaq: AUTL), a clinical-stage biopharma and a portfolio company of Syncona Ltd., has announced that

Autolus announces primary endpoint met in FELIX trial, prices public offering

https://pharmaphorum.com/news/autolus-announces-primary-endpoint-met-in-felix-trial-prices-public-offering/

News/ News/ News/ Oncology/ R&D

Sanofi backs out of $500m cancer alliance with Revolution

Phil Taylor immuno-oncology, KRAS, Oncology, partnering, Revolution Medicines, Sanofi, SHP2 0 Comment

Sanofi has walked away from a four-year-old partnership with Revolution Medicines focused on an SHP2 inhibitor, intended as

Sanofi backs out of $500m cancer alliance with Revolution

https://pharmaphorum.com/news/sanofi-backs-out-of-500m-cancer-alliance-with-revolution/

News/ News/ News/ Oncology/ R&D

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC

Phil Taylor GSK, immuno-oncology, Jemperli, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology 0 Comment

GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC

https://pharmaphorum.com/news/gsk-trumpets-jemperli-vs-keytruda-data-in-first-line-nsclc/

News/ News/ News/ Oncology/ R&D

Little Summit Therapeutics spends big bucks to rebuild pipeline

Phil Taylor Akeso, bispecific antibody, immuno-oncology, licensing, Non-small cell lung cancer, Oncology, Summit Therapeutics 0 Comment

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made

Little Summit Therapeutics spends big bucks to rebuild pipeline

https://pharmaphorum.com/news/little-summit-therapeutics-spends-big-bucks-to-rebuild-pipeline/

1200px-Human_Natural_Killer_Cell_(29120480442)

News/ News/ News/ Oncology/ R&D

New Nkarta data backs up natural killer approach to cancer treatment

Phil Taylor car-nk, immuno-oncology, natural killer cells, Nkarta, non-Hodgkin lymphoma, Oncology 0 Comment

Harnessing the power of natural killer (NK) cells to attack cancer is as-yet an unproven strategy in oncology

New Nkarta data backs up natural killer approach to cancer treatment

https://pharmaphorum.com/news/new-data-backs-up-nkarta-natural-killer-approach-to-cancer/

Cancer/ News/ News/ News/ Oncology/ R&D

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

Nicole Raleigh Novartis, Oncology, Pluvicto, Prostate cancer, PSMAfore study, radioligand therapy, VISION study 0 Comment

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

https://pharmaphorum.com/news/novartis-pluvicto-presents-survival-benefit-for-castration-resistant-prostate-cancer/

Market Access/ News/ News/ News/ News/ Oncology/ R&D

GSK cancer division delivers good news after string of R&D setbacks

Phil Taylor endometrial cancer, GlaxoSmithKline, immuno-oncology, Jemperli, momelotinib, myelofibrosis, Oncology 0 Comment

GSK has reported much-needed progress with two of its cancer therapies, with a phase 3 trial win for

GSK cancer division delivers good news after string of R&D setbacks

https://pharmaphorum.com/news/gsk-cancer-division-delivers-good-news-after-string-of-rd-setbacks/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

Login